Every 8-K that Amedisys Inc (AMED) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AMED and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMED filings page.
Amedisys completed a cash sale to UnitedHealth Group, effective August 14, 2025. Each outstanding share of Amedisys common stock was converted into the right to receive $101.00 per share in cash, less applicable withholding. At the Effective Time Amedisys became an indirect, wholly owned subsidiary of UnitedHealth Group.
The company terminated its senior secured credit facilities and paid an aggregate of $399,191,391.35 to satisfy outstanding obligations. Amedisys notified Nasdaq to suspend trading, withdraw its listing and file Form 25, and intends to file Form 15 to deregister and suspend reporting. Outstanding equity awards generally converted into UnitedHealth-denominated awards using an exchange ratio tied to the cash consideration and UnitedHealth stock trading levels; director RSU awards were canceled for cash equal to the per-share consideration. Several directors resigned as required by the merger agreement. Financial and transaction documents and counsel are noted in the filing.
On 7 Aug 2025 the U.S. Department of Justice and the Attorneys General of MD, IL, NJ and NY filed a Proposed Final Judgment with the U.S. District Court for Maryland. The order—agreed to by Amedisys (AMED) and UnitedHealth Group—would settle the government’s antitrust lawsuit against their June 26 2023 merger agreement (waiver dated 26 Dec 2024). If approved, the companies must divest specified assets within 75 days of an Asset Preservation/Hold-Separate order, or within 60 days after all Indiana and West Virginia clearances, whichever is later.
The judgment requires court approval under the Antitrust Procedures and Penalties Act and the merger still depends on the remaining closing conditions in the Merger Agreement. No financial results, consideration changes or new guidance were provided.
- Filing: Form 8-K, Item 8.01 – Other Events
- Ticker: AMED; Exchange: NASDAQ Global Select
- Key risks noted: potential deal termination, regulatory delays, litigation, integration distraction and inability to complete divestitures.
Implication: The settlement framework reduces regulatory uncertainty but completion risk persists until the court rules and divestiture terms are executed.